Stockholm 21 Nov 2019
|Date:||Thursday 21 November 2019|
|Time:||14.00–17.15 and a following mingle|
|Location:||Spårvagnshallarna, Birger Jarlsgatan 57 A, Stockholm|
|Cost:||Free of Charge|
|Registration:||No later than November 15th. Go to: https://tinyurl.com/y4dlwjft|
We are excited to invite you to a workshop that will be of great value for every stakeholder that has aspirations within cancer therapy development. GCP, GMP, GLP may rule our standard procedures. However, it is strategies, tactics and the management of the regulatory landscape as well as project execution, that will make your ideas successful. We are delighted to have such an experienced key panel present at our workshop. Together they represent companies that has contributed to more than 400 project into clinical phase and now they will share their precious findings with us!
Our key note speaker Dr Magnus Björsne, will let us know about the change in Big Pharma strategy and furnish a discussion on how that may influence the strategies of our drug development projects.
Welcome to contribute and share your thoughts with others!
Most presentations will be held in Swedish.
Moderator Viktor Backemar, Groth & Co
14.10 Preclinical chemistry development of oncology projects – from the CRO perspective.
Jonas Malmström, Recipharm
14.30 First in man preclinical package – the dynamics in preparations for successful study protocol
Dr Enrico Pesenti, Accelera
14.50 First in man clinical execution – 250 drugs in the clinic, take home message
Dr Jack Welch, Theradex Oncology
15.40 IP – Strategies to obtain exclusivity
Dr Malin Boström and Carl Wendt, Groth & Co
16.00 The art of naming pharmaceutical products
Olof Lindquist, Skriptor Zigila
16.20 Short break
16.25 What about if assumptions on industry expectations suddenly are wrong…
Dr Magnus Björsne, CEO, AstraZeneca BioVentureHub
16.55 Panel discussion
17.15 Mingle, buffet and drinks